Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

Feb. 23, 2021, 1:47 p.m. EST

Meridian Bioscience issues correction: It can't ship its Revogene SARS-CoV-2 test until EUA is granted

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Meridian Bioscience Inc. (VIVO)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Meridian Bioscience Inc. /zigman2/quotes/202928219/composite VIVO +0.02% issued a statement Tuesday afternoon, to correct a statement made earlier regarding its SARS-CoV-2 molecular diagnostic test on its Revogene platform. The stock dropped 8.7%, and has now tumbled 30.0% since it closed on Feb. 11 at the highest price since October 2008. After speaking with the Food and Drug Administration mid-morning Tuesday, the company said it will not be able to distribute its Revogene SARS-CoV-2 test until the test receives Emergency Use Authorization approval from the FDA. Earlier Tuesday, the company had said it would resume shipping of the tests once it notifies the FDA of its intent to re-submit an EUA application. The company said Tuesday that it had decided to withdraw its EUA application following further discussions with the FDA, which comes a week after the company said the FDA requested additional information on the test. Despite the recent selloff, Meridian's stock has still climbed 19.5% over the past three months, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -2.00% has gained 7.7%.

/zigman2/quotes/202928219/composite
US : U.S.: Nasdaq
$ 20.09
+0.0050 +0.02%
Volume: 956,064
Nov. 30, 2021 3:53p
P/E Ratio
12.48
Dividend Yield
0.00%
Market Cap
$870.76 million
Rev. per Employee
$418,284
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,562.07
-93.20 -2.00%
Volume: 2.48B
Nov. 30, 2021 3:54p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.